Cancer is a major problem in the western world and most of the established anticancer treatments are non-selective and affects healthy cells, causing adverse effects. The biotech sector has made significant advances in oncology, particularly with regard to antibody-based therapeutics. This feature considers the targeted oncological treatments and their benefits and hurdles.